Scientists test new therapy VY1706 on humans to stop the progression of Alzheimer’s

Biotechnology company Voyager Therapeutics, Inc. revealed on Monday, July 13, 2026, promising data from a six-month toxicology study for VY1706, an experimental gene therapy. The results indicate that a single intravenous dose of the treatment was well tolerated in non-human primates and managed to reduce tau protein by up to 75% in crucial brain regions. The company plans to begin a clinical trial for Alzheimer’s disease in the second half of this year. The detailed presentation was made during the 2026 Alzheimer’s Association International Conference (AAIC) in London.
The United States Food and Drug Administration (FDA) in June granted Investigational New Drug (IND) authorization for VY1706. This regulatory approval allows Voyager Therapeutics to begin the clinical trial in adults with early-stage Alzheimer’s disease, with the first dose expected in the second half of 2026. In May, the company had already released three months of toxicology data for VY1706 at the 2026 Annual Meeting of the American Society for Cell and Gene Therapy (ASGCT), reinforcing the initial safety and efficacy profile.
Alfred W. Sandrock, Jr., MD, Ph.D., CEO of Voyager, said the AAIC data “continue to reinforce the compelling pharmacological, safety and durability profile” seen with VY1706, noting that it is the first gene therapy targeting tau protein to receive an FDA-approved IND. The executive emphasized tau protein as a “potentially transformative target in Alzheimer’s disease” and expressed optimism about the beginning of the clinical phase.
Advances in developing therapies for neurological diseases
VY1706 demonstrated a favorable tolerability profile in 3- and 6-month toxicology studies conducted in accordance with Good Laboratory Practices (GLP) in non-human primates. No adverse clinical or histopathological findings were observed in the central nervous system, dorsal root ganglia, or peripheral organs such as the liver, even at the highest tested dose of 5E13 vg/kg.
A single intravenous dose of VY1706 in non-human primates achieved broad and long-lasting distribution in the central nervous system, with a dose-dependent reduction of up to 75% of MAPT mRNA and tau protein in brain regions relevant to Alzheimer’s disease over six months.
The mechanism of VY1706 transport across the blood-brain barrier (BBB) is mediated by ALPL, a well-conserved endothelial receptor of the cerebral vasculature. This finding reinforces the potential for translatability between species, indicating that the results may be applicable to humans.
Complete information from the Emerging Topics poster presentation was made available by Voyager Therapeutics following the conference.

Details about VY1706 gene therapy
VY1706 is an experimental gene therapy designed for Alzheimer’s disease, focusing on the tau protein, which is linked to neurodegeneration and cognitive decline. At its core, VY1706 uses a potent vectorized siRNA to decrease levels of tau protein, both intracellular and extracellular, in the brain. This siRNA is encapsulated in Voyager’s AAV TRACER capsid, which employs the ALPL receptor to deliver the treatment to the brain after a single intravenous dose. In comprehensive preclinical testing, VY1706 showed good tolerability and reduced tau protein by up to 75% in brain areas important for Alzheimer’s disease in non-human primates without impacting the liver, which is a significant benefit compared to other systemic gene therapies.






